This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic approaches, the value and limitations of mutation screening for diagnostic and prognostic purposes, risk stratification in terms of both survival and other disease complications such as leukemic transformation and thrombosis, and modern therapeutic strategies, including conventional drugs, allogeneic stem cell transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.
Presentation of the myeloproliferative neoplasms (MPNs) varies widely, and correct diagnosis and management can be challenging, and is becoming more complex as understanding of the underlying molecular basis for these disorders emerges. Appropriate management is increasingly informed by accurate risk stratification founded on understanding of cytogenetic and molecular markers, as well as the clinical presentation. 'Fast Facts: myeloproliferative neoplasms' focuses on the three most common chronic MPNs: • Essential thrombocythemia (ET) – characterized by increased platelet count • Polycythemia vera (PV) – characterized by excessive production of red blood cells • Primary myelofibrosis – a more severe and heterogenous disorder that may overlap with ET and PV but is commonly associated with anemia. Written by two leading experts in the field, Fast Facts: myeloproliferative neoplasms provides concise, up-to-date and practical guidance on the accurate diagnosis, risk stratification and management of these MPNs. It also provides key insights into our growing understanding of the underlying molecular and genetic basis of these disorders, and how this is informing risk stratification and management strategies. This concise handbook will be invaluable to clinicians, medical students, nurses, pharmacists and scientists in understanding and overcoming the everyday and rarer challenges associated with MPN.
With the new classification of chronic myeloproliferative disorders, and the rise of interest in molecularly targeted therapies, this timely text brings together international experts on the topic to discuss the current technologies and their implications for the treatment of patients. This title comprehensively covers chronic myeloid leukemia and Ph-negative chronic myeloproliferative disorders and is an essential resource for all practitioners in Hematologic Oncology.
Cancer care today often provides state-of-the-science biomedical treatment, but fails to address the psychological and social (psychosocial) problems associated with the illness. This failure can compromise the effectiveness of health care and thereby adversely affect the health of cancer patients. Psychological and social problems created or exacerbated by cancer-including depression and other emotional problems; lack of information or skills needed to manage the illness; lack of transportation or other resources; and disruptions in work, school, and family life-cause additional suffering, weaken adherence to prescribed treatments, and threaten patients' return to health. Today, it is not possible to deliver high-quality cancer care without using existing approaches, tools, and resources to address patients' psychosocial health needs. All patients with cancer and their families should expect and receive cancer care that ensures the provision of appropriate psychosocial health services. Cancer Care for the Whole Patient recommends actions that oncology providers, health policy makers, educators, health insurers, health planners, researchers and research sponsors, and consumer advocates should undertake to ensure that this standard is met.
The field of oncology benefits from several large-scale reference books and a host of monographs dedicated to specific cancers. However, truly excellent practice and review books are, surprisingly, quite scarce. Outside of a scant handful of books and online reference tools that offer clinical response practice and board review in a basic question and answer format, there are no resources that offer a robust, engaging, fully referenced tool for these vital activities in every oncologist’s and oncology trainee’s work. This print and electronic book seeks to fill that void, offering comprehensive question-and-answer style content that covers the entire specialty of oncology and provides practicing oncologists with a fascinating and immediately applicable compendium of vital information dealing with a well-balanced selection of common and uncommon cancers. At the heart of this book is the editor’s and authors’ desire to overcome the controversies and barriers to practice that usually emerge following the appearance of new data. In every section, the user is guided toward collaboration in ongoing clinical research – for example, via discussions of well-designed ongoing clinical trials in each specific area. Developed with both the teacher and learner in mind, this book also offers trainees and fellows an excellent opportunity to enhance their preparation for the ABIM oncology fellowship exam as well as for the oncology boards. It will also be an extremely useful tool for oncologists working toward the recertification exam. This comprehensive, beefy book includes hundreds of painstakingly developed multiple-choice and mini-case-based questions covering the principles of medical oncology, malignant hematology, surgical oncology, and radiation oncology. It also contains mini-cases and questions dealing with the biology, diagnosis, classification, staging, and multidisciplinary treatment of cancers at every anatomic site. The very latest topics are included, such as molecular techniques, targeted therapies, and translational cancer research. Concise but detailed answers are referenced to key journals and books, and evidence-based wherever possible. NCCN guidelines are also referenced as appropriate. With its powerful focus on take-home messages from and for actual clinical work, this book will help keep oncologists up to date, bridging the gaps between journal and reference literature, conferences, and their existing knowledge base.
This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students.
This comprehensive, superbly illustrated reference is designed to provide practical diagnostic assistance for hematopathologists when dealing with common and uncommon lesions in bone marrow trephine biopsies (BMTBs). At the heart of the book is a systematic analysis of neoplastic hematological and non-hematological disease entities, with concise identification of the key features of myeloproliferative neoplasms, myelodysplastic syndromes, acute and chronic leukemias, eosinophilia-associated myeloid/lymphoid neoplasms, lymphoproliferative disorders, and selected non-hematopoietic malignancies. Relevant examples of BMTBs are presented, with microscopic description, high-quality photomicrographs, and clinical data. The book also explains how to assess hematopoietic and stromal components of normal BMTBs, identifies the heterogeneous patterns that may be observed in healthy individuals, and analyzes reactive conditions, with particular attention to diagnostic problems and pitfalls.
Showcasing the expertise of top-tier specialists who contributed to the newly released guidelines for the care of thrombosis in cancer patients, this exciting guide was written and edited by members of the American Society of Clinical Oncology panel, (ASCO), on the prevention and treatment of cancer-associated thrombosis, among others, and provides
